Co-Diagnostics, Inc.
CODX
Rank in Stocks
#31904
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops,... Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Share Price
$0.319
Last synced: 2026-11-09
Market Cap
$2.38M
Change (1 day)
24.22%
Change (1 year)
-97.30%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Co-Diagnostics, Inc. (CODX)
Category
Healthcare
Earnings for Co-Diagnostics, Inc. (CODX)
Earnings in Jun 2026 TTM: $-48.68M
According to Co-Diagnostics, Inc.'s latest financial reports, its current earnings (TTM) are $-48.68M. In 2025 the company earned $-48.51M, a decrease compared to its 2024 earnings of $-37.58M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Co-Diagnostics, Inc. from 2014 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-48.68M | 0.34% |
| 2025 | $-48.51M | 29.08% |
| 2024 | $-37.58M | -1.39% |
| 2023 | $-38.11M | 102.21% |
| 2022 | $-18.85M | -141.30% |
| 2021 | $45.64M | 7.20% |
| 2020 | $42.57M | -787.09% |
| 2019 | $-6.20M | -1.21% |
| 2018 | $-6.27M | -9.88% |
| 2017 | $-6.96M | 260.83% |
| 2016 | $-1.93M | -5.60% |
| 2015 | $-2.04M | 94.94% |
| 2014 | $-1.05M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $4.76B | -9,877.72% |
US
|
|
| $-2.73B | 5,506.34% |
US
|
|
| $-4.02B | 8,150.71% |
AU
|
|
| $2.83B | -5,905.25% |
BE
|
|
| $1.50B | -3,175.26% |
NL
|
Questions about Co-Diagnostics, Inc.'s net income
What is Co-Diagnostics, Inc.'s net income?
Co-Diagnostics, Inc.'s net income over the last twelve months is $-48.68M, as of Jun 2026.
What was Co-Diagnostics, Inc.'s net income in 2025?
In 2025, Co-Diagnostics, Inc.'s net income was $-48.51M, compared with $-37.58M in 2024.
How has Co-Diagnostics, Inc.'s net income changed since 2020?
From 2020 to 2025, Co-Diagnostics, Inc.'s net income was highest in 2021 ($45.64M) and lowest in 2025 ($-48.51M).
How does Co-Diagnostics, Inc.'s net income compare with similar companies?
Co-Diagnostics, Inc.'s net income ($-48.68M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.